4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Metagenomi Therapeutics, Inc. (MGX) operates in the Biotechnology industry and is headquartered in EmeryVille, United States with about 118 employees. Its market capitalization is roughly $46 million. In the fiscal year ended 2025-12-31, MGX reported $25M in revenue and ($88M) in net income.
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia.
Interactive charts & full statements → Open the MGX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $25M | $52M | $45M | $17M | — |
| Operating Income (EBIT) | ($96M) | ($89M) | ($78M) | ($45M) | — |
| Net Income | ($88M) | ($78M) | ($68M) | ($44M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $1M | $4M | $9M | $8M | $4M | — |
| Operating Income (EBIT) | ($25M) | ($24M) | ($23M) | ($21M) | ($28M) | — |
| Net Income | ($23M) | ($22M) | ($20M) | ($20M) | ($25M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $221M | $325M | $365M | $414M | — |
| Total Liabilities | $62M | $90M | $500M | $489M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MGX viewer.
About TickerBase · Data methodology & sources